BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37660477)

  • 21. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma.
    Mei Z; Zhang K; Lam AK; Huang J; Qiu F; Qiao B; Zhang Y
    Cancer Med; 2020 Jan; 9(2):640-652. PubMed ID: 31800160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.
    Khuisangeam N; Jewmoung S; Thaiwong R; Tudsamran S; Hirankarn N; Suppipat K; Tawinwung S
    J Immunol Res; 2022; 2022():2449373. PubMed ID: 36457849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional characterization and development of novel human kinase insert domain receptor chimeric antigen receptor T-cells for immunotherapy of non-small cell lung cancer.
    Zhong M; Chalbatani GM; Deng M; Li Q; Gharagouzloo E; Hamblin MR; Suarez ER; Hu L; Wang D
    Eur J Pharm Sci; 2023 Jan; 180():106331. PubMed ID: 36384203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Engineered T cells for pancreatic cancer treatment.
    Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
    HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
    Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
    Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice.
    Li H; Huang Y; Jiang DQ; Cui LZ; He Z; Wang C; Zhang ZW; Zhu HL; Ding YM; Li LF; Li Q; Jin HJ; Qian QJ
    Cell Death Dis; 2018 Feb; 9(2):177. PubMed ID: 29415996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
    Sanchez C; Chan R; Bajgain P; Rambally S; Palapattu G; Mims M; Rooney CM; Leen AM; Brenner MK; Vera JF
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):123-31, S1. PubMed ID: 23295316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on construction of c-Met specific CAR-T cells and its killing effect on non-small cell lung carcinoma].
    Min JT; Zhang L; Long CR; Fan HL; Li ZZ
    Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):322-329. PubMed ID: 37078213
    [No Abstract]   [Full Text] [Related]  

  • 33. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
    Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
    J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSCA is a target of chimeric antigen receptor T cells in gastric cancer.
    Wu D; Lv J; Zhao R; Wu Z; Zheng D; Shi J; Lin S; Wang S; Wu Q; Long Y; Li P; Yao Y
    Biomark Res; 2020; 8():3. PubMed ID: 32010446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
    Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
    Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
    J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.